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Abstract
AIM: To explore the anti-inflammatory potential of 
adeno-associated virus-mediated delivery of Tregitope 
167 in an experimental colitis model. 
METHODS: The trinitrobenzene sulfonate (TNBS) 
model of induced colitis was used in Balb/c mice. Sub-
sequently after intravenous adeno-associated virus-
mediated regulatory T-cell epitopes (Tregitope) delivery, 
acute colitis was initiated by intra-rectal administration 
of 1.5 mg TNBS in 40% ethanol followed by a second 
treatment with TNBS (0.75 mg in 20% ethanol) 8 d lat-
er. Control groups included mice not treated with TNBS 
(healthy control group) and mice treated by TNBS only 
(diseased group). At the time of sacrifice colon weight, 
the disease activity index and histology damage score 
were determined. Immunohistochemical staining of the 
colonic tissues was performed to asses the cellular infil-
trate and the presence of transcription factor forkhead 
Box-P3 (Foxp3). Thymus, mesenteric lymph nodes, liver 
and spleen tissue were collected and the corresponding 
lymphocyte populations were further assessed by flow 
cytometry analysis for the expression of CD4+ T cell 
and regulatory T cell associated markers.
RESULTS: The Tregitope 167 treated mice gained an 
average of 4% over their initial body weight at the 
time of sacrifice. In contrast, the mice treated with 
TNBS alone (no Tregitope) developed colitis, and lost 
4% of their initial body weight at the time of sacrifice (P  
< 0.01). The body weight increase that had been ob-
served in the mice pre-treated with Tregitope 167 was 
substantiated by a lower disease activity index and a 
decreased colon weight as compared to the diseased 
control group (P  < 0.01 and P  < 0.001, respectively). 
Immunohistochemical staining of the colonic tissues 
for CD4+ showed that inflammatory cell infiltrates 
were present in TNBS treated mice with or without 
administration with tregitope 167 and that these cel-
lular infiltrates consisted mainly of CD4+ cells. For 
both TNBS treated groups CD4+ T cell infiltrates were 
observed in the sub-epithelial layer and the lamina 
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propria. CD4+ T cell infiltrates were also present in 
the muscularis mucosa layer of the diseased control 
mice, but were absent in the Tregitope 167 treated 
group. Numerous Foxp3 positive cells were detected 
in the lamina propria and sub-epithelium of the colon 
sections from mice treated with Tregitope 167. Fur-
thermore, the Foxp3 and glycoprotein A repetitions 
predominant markers were significantly increased in 
the CD4+ T lymphocyte population in the thymus of 
the mice pre-treated with adeno-associated virus se-
rotype 5 (cytomegalovirus promoter-Tregitope 167), 
as cytomegalovirus promoter compared to lymphocyte 
populations in the thymus of diseased and the healthy 
control mice (P  < 0.05 and P  < 0.001, respectively).
CONCLUSION: This study identifies adeno-associated 
virus-mediated delivery of regulatory T-cell epitope 167 
as a novel anti-inflammatory approach with the capac-
ity to decrease intestinal inflammation and induce long-
term remission in inflammatory bowel disease. 
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Inflammatory bowel diseases (IBD) are inflammatory 
diseases that affect mostly young adults[1,2]. Although the 
precise pathogenesis has not been identified, it is gener-
ally accepted that IBD result from inappropriate mucosal 
immune system responses against intestinal flora and 
other luminal antigens[3-5]. IBD are associated with a re-
duction in quality of  life[6-8] and no curative treatments 
are available. 
Despite the fact that novel treatment strategies, in-
cluding tumor necrosis factor (TNF)-neutralizing anti-
bodies, have greatly expanded the therapeutic armamen-
tarium, these therapeutics do not prevent complications 
in IBD and many patients still have to undergo surgery[9]. 
New treatment strategies that would prevent the initiation 
of  inflammation and enable long-term remission would 
improve the lives of  millions of  individuals who are af-
fected by IBD world-wide[10,11].
Recently, biological therapies that target immune path-
ways have emerged as a new therapeutic approach for the 
treatment of  immune-mediated diseases. They include 
administration of  monoclonal antibodies against inflam-
matory cytokines[12] and those that influence immune 
responses such as certain small molecules, Helminths 
and stem cells[10,13,14]. Since IBD are immune-mediated 
diseases, these biological therapies are highly promising 
treatment approaches and have the potential to achieve 
mucosal tolerance and long-term remission in IBD[10,12-14]. 
Here, we introduce regulatory T-cell epitopes (Tregi-
topes)[15,16] as novel biological agents that could create 
new possibilities for the regulation of  inflammation and 
postulate that Tregitopes, delivered by adeno-associated 
virus (AAV), could be developed as a new therapeutic 
modality for the treatment of  IBD. 
Tregitopes are a set of  putative regulatory T cell 
epitopes present in the immunoglobulin G molecule, 
which have been identified by using computational epi-
tope mapping[15,16]. Tregitope sequence 167 (Tregitope 
167) and an additional sequence (Tregitope 289) were 
synthesized and shown to bind to multiple Major Histo-
compatibility complex (MHC) class Ⅱ molecules and to 
suppress immune response when co-administered with 
an antigen. Tregitopes 167 and 289 were also shown to 
expand natural occurring regulatory T (nTreg) cells and 
to induce a regulatory phenotype and function in pe-
ripheral T (iTreg) cells[15,16]. Harnessing the potential of  
Treg cells activated or induced by Tregitopes to regulate 
pathological immune responses in IBD may reduce the 
requirement for systemic immunosuppressive therapies. 
However, the use of  immunomodulatory peptides in 
clinical applications for IBD so far have shown that the 
in vivo delivery of  these peptides for therapeutic pur-
poses is hindered by difficulties in obtaining sufficient 
and stable peptide concentrations[17-19]. Therefore, novel 
means for stable delivery of  regulatory peptides have to 
be explored. AAV present a good safety profile and have 
been shown to be effective as gene delivery vectors in 
the clinic for the treatment of  a broad range of  diseas-
es[20-22]. Therefore, AAV-mediated delivery represents an 
attractive approach to deliver the immuno-modulatory 
Tregitope peptides.
In the present study, the potential of  AAV-mediated 
gene therapy for the therapeutic delivery of  Tregitope 
167 was explored. Systemic AAV-mediated administration 
of  Tregitope 167 was shown to ameliorate the clinical and 
histo-pathological severity of  trinitrobenzene sulfonate 
(TNBS) induced inflammatory colitis in mice. Hence, 
AAV-mediated delivery of  regulatory T-cell epitopes ap-
pears to be a promising novel therapeutic approach for 
the treatment of  IBD and could represent an alternative 
or adjunct to the use of  immunosuppressive drugs.
MATERIALS AND METHODS
AAV vector production and characterization
Mouse Tregitope cDNA was synthesized (Integrated 
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DNA Technologies, IDT, Inc) according to the published 
corresponding sequence[15,16] and cloned into the plasmid 
pPSC10[23] under the control of  the cytomegalovirus 
(CMV) promoter. The Woodchuck hepatitis virus post-
transcriptional enhancer was incorporated behind the 
Tregitope 167 cDNA to further optimize gene expres-
sion[24]. The AAV vector, AAV5 (CMV-Tregitope 167) 
was produced according to a technology adapted from 
Negrete et al[23]. The AAV vector was purified with an 
anion column using the ÄKTA explorer system (GE-
Healthcare). After purification, the concentration of  
AAV vector genomes copies (genome copies/mL) was 
determined at 9 × 1013 genome copies/mL by Taqman 
qPCR amplification. The biological infectivity of  AAV5 
(CMV-Tregitope 167) was demonstrated in vitro by PCR 
amplification of  the “CMV-Tregitope 167” DNA frag-
ment (product size 402 bp) on DNA isolated from 
HEK293T transduced with AAV5 (CMV-Tregitope 167). 
Primers designed and synthesized for Tregitope 167 and 
the CMV promoter were used.
Induction of colitis and study design
Balb/c mice (males, age 6-8 wk) were obtained from 
Harlan Laboratories, the Netherlands. The experimen-
tal protocol was approved by the ethical committee for 
animal welfare of  the AMC (Academic Medical Center, 
Amsterdam, the Netherlands). Colitis was induced in 
mice by administration of  TNBS (TNBS, Sigma-Aldrich), 
as described previously[25]. The general procedure is sum-
marized in Figure 1.
Mice were injected intravenously with either phos-
phate-buffered saline or AAV5 (CMV-Tregitope) 10 d 
before acute colitis was initiated by intra-rectal adminis-
tration of  1.5 mg TNBS in 40% ethanol. Consecutively, 
a second TNBS treatment (0.75 mg in 20% ethanol) was 
done 8 d after the first TNBS treatment as described 
precedently[25]. Mice not treated with TNBS (healthy con-
trol group) and mice treated with TNBS only (diseased 
control group) were used as references to monitor colitis 
development. A concomitant sham AAV control vector 
was not used in this study as this control has been shown 
to be equivalent to saline control[26,27]. Even though AAV-
mediated gene transfer leads to the development of  neu-
tralizing antibodies against the vector capsid[28], prevent-
ing vector re-administration, no inflammatory responses 
against the AAV capsid were documented in in vivo gene 
transfer mice models using AAV vectors[27,29]. 
Assessment of inflammation
The body weights of  the mice were recorded daily, and 
wasting disease progression was expressed by the per-
centage of  weight loss as compared to body weight at 
the day of  initiation of  TNBS treatment (day 10, Figure 
1). Animals were withdrawn from the study when their 
weight loss was > 25% of  their original body weight. At 
the time of  sacrifice, colons were collected and presence 
of  loose stool and visible fecal blood was assessed.
At the time of  sacrifice, a composite score [disease 
activity index (DAI)] was established as described previ-
ously[25]. Body weight loss was scored on a scale of  0-4 (0, 
< 1%; 1, 1%-5%; 2, 5%-10%; 3, 10%-15%; 4, > 15%). 
Loose stool was scored on a scale of  0-4 (0, normal; 1, 
loose droppings; 2, loose stools, colon filled with feces; 
3, loose stool, feces only near cecum; 4, empty bowel). 
Visible fecal blood was scored on a scale of  0-4 (0, nega-
tive; 2, positive; 4, gross bleeding). The DAI consists of  a 
combination of  body weight loss, loose stool and visible 
fecal blood scores divided by 3 as described previously[25].
Colon tissue weights were recorded and used as an 
indicator of  disease-related intestinal wall thickening. 
Increased colon weight has been shown to correlate with 
increased colon inflammation[25]. Colons were first di-
vided longitudinally into two parts: one part was immedi-
ately frozen in liquid nitrogen for protein extraction and 
cytokine determination, while the second part was stored 
in formalin and embedded in paraffin for (immuno-) 
histological evaluation. Blood was collected by orbital 
puncture immediately following sacrifice and plasma 
was separated by centrifugation (5000 r/min for 5 min). 
Plasma samples were stored at -80 ℃ until analysis.
Histological analysis
Colonic segments were fixed in 10% formalin overnight 
and thereafter stored in 70% ethanol before embedding 
in paraffin. Tissues sections (7 μm thick) were stained 
with haematoxylin and eosin (HE) for histology scoring. 
The histology damage score was calculated using the fol-
lowing criteria: percentage of  area involved, number of  
follicle aggregates, edema, fibrosis, erosion/ulceration, 
crypt loss, and infiltration of  mononuclear and polymor-
phonuclear cells, as described previously[30]. The percent-
age of  area involved and crypt loss were scored on a scale 
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Day 0 Day 10 Day 18 Day 20
AAV5 injection, to ensure 
that on the day of  the colitis 
induction the Tregitope are 
being expressed
Intra-anal 1.5 mg TNBS 
in 40% ethanol, for the 
induction of acute colitis
Intra-anal 0.75 mg TNBS in 
20% ethanol 
Termination of experiment
Figure 1  Schematic overview of the trinitrobenzene sulfonate induced colitis model. Mice were injected intravenously with either phosphate-buffered saline (PBS) 
or adeno associated virus (AAV) 5 [cytomegalovirus (CMV) promoter T-cell epitopes (Tregitope) 167]. Ten days after AAV-mediated Tregitope delivery acute colitis was 
initiated by intra-rectal administration of 1.5 mg trinitrobenzene sulfonate (TNBS) in 40% ethanol followed by a second TNBS treatment (0.75 mg in 20% ethanol) 8 d 
later. Control groups consisted of mice not treated by TNBS (healthy control group) and mice treated by TNBS only (diseased control group). 
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severity and is indicative of  differences in colitis develop-
ment between experimental groups[31]. Animals were with-
drawn from the study when their weight loss was > 25% 
of  their original body weight. 
The body weight of  the mice was monitored daily 
after the first TNBS treatment as an indication of  the 
severity in the colitis development between experimen-
tal groups (Figure 2). TNBS treated mice that were pre-
administered with Tregitope 167, showed a body weight 
that increased over time and was comparable to the weigh 
gain of  untreated healthy control mice (Figure 2). The 
Tregitope 167 treated mice gained an average of  4% over 
their initial body weight at the time of  sacrifice (Figure 
3A). In contrast, the mice treated with TNBS alone (no 
Tregitope) developed colitis, and lost 4% of  their initial 
body weight at the time of  sacrifice (Figure 3A). 
Increases in colon weight, as well as in the disease 
activity index are both indicative of  colonic inflammation 
and were determined at the time of  sacrifice (Figure 3). 
The body weight increase that had been observed in the 
mice pre-treated with Tregitope 167 was substantiated by 
a lower disease activity index (Figure 3B) and a decreased 
colon weight (Figure 3C) as compared to the diseased 
control group (P < 0.01 and P < 0.001 respectively).
The histology damage score was performed on HE 
of  0-4 (0, normal; 1, < 10%; 2, 10%; 3, 10%-50%; and 4, 
> 50%). Erosions were defined as 0 if  the epithelium was 
intact, 1 if  the lamina propria was involved, 2 if  ulcer-
ations involved the submucosa, and 3 when ulcerations 
were transmural. The severity of  the other parameters 
was scored on a scale of  0-3 (0, absent; 1, weak; 2, mod-
erate; and 3, severe)[30]. A certified pathologist scored all 
the tissue sections (blinded analysis).
Immunohistochemistry
Colon tissues sections of  7 μm were aceton-fixed and sta-
ined with rat-anti-mouse (ram) CD4 (1:100, BD550278), 
ram CD8a (1:50, BD550281), ram CD19 (1:50, 
BD550284), ram Foxp3 (1:100, eBiosciences14-5773-82) 
and ram F4/80 (1:500). Prior to anti-rat biotin conjugated 
secondary antibody (1:50, BD51-7605kc) and Streptavi-
din-HRP (BD) incubations, endogenous peroxidases were 
blocked by incubation with 0.3% H2O2 for 20 min. After 
5 min of  diaminobenzidine staining (BD), the sections 
were counter-stained with Haematoxylin, dehydrated and 
mounted in Entallan.
Flow cytometry
Thymus, mesenteric lymphoid nodes, liver and spleen 
tissue were collected upon sacrifice. Cell suspensions 
obtained from each of  the tissue samples were prepared 
using 40 μm cell strainers (BD Biosciences) and stained 
for T cell surface markers CD4 (clone RM4-5, eBiosci-
ence), CD8 (Clone 53-6.7, Miltenyi) and Treg cell surface 
markers glycoprotein A repetitions predominant (GARP) 
and CD25 (clone YGIC86 and clone PC61.5 respectively, 
both eBioscience) as well as for the intracellular Treg cell 
marker Foxp3 (clone FJK16, eBioscience). The analysis 
was performed by flow cytometry (FACSCalibur, BD 
Biosciences). 
Statistical analysis
The results are presented as mean ± SD or SE, where 
appropriate. Statistical analyses were performed using 
Prism 5.0 (GraphPad). Data were analyzed using a 1 way 
analysis of  variance, followed by Dunn’s post hoc test for 
multiple comparisons.
RESULTS
We investigated the potential for AAV5-mediated delivery 
of  regulatory T-cell epitopes to prevent the development 
of  TNBS induced colitis. Mice treated intra-rectally with 
TNBS in ethanol developed a severe illness as reflected in 
the progressive body weight loss over time and an increase 
in disease activity index, histology damage score and mu-
cosal inflammatory parameters at the time of  sacrifice.
Tregitope 167 delivery protects against TNBS colitis 
development
Development of  colitis in the TNBS mice model is str-
ongly associated with wasting disease[31]. Daily weight 
determination is therefore important to determine colitis 
Figure 2  Adeno associated virus serotype 5 mediated delivery of regula-
tory T-cell epitope 167 ameliorates trinitrobenzene sulfonate induced 
colitis development over time. Mice were injected intravenously with either 
phosphate-buffered saline (PBS) or adeno associated virus (AAV) 5 [cytomega-
lovirus (CMV) promoter T-cell epitopes (Tregitope) 167]. 10 d after AAV-mediat-
ed Tregitope delivery, acute colitis was initiated by intra-rectal administration of 
1.5 mg trinitrobenzene sulfonate (TNBS) in 40% ethanol followed by a second 
TNBS treatment (0.75 mg in 20% ethanol) 8 d later. Control groups consisted 
of mice not treated by TNBS (healthy control group) and mice treated by TNBS 
only (diseased control group). Disease progression was assessed by changes 
in daily body weight. Animals were withdrawn from the study when their weight 
loss was > 25% of their original body weight. Overall for the healthy controls, 
n = 9; adeno associated virus (AAV) 5 (CMV-Tregitope 167) treated, n = 7; 
diseased controls, n = 6, were included in the analysis. The data were analyzed 
using a 1 way analysis of variance, followed by Dunn’s post hoc test for multiple 
comparisons. Data are presented as mean ± SE of all the mice. bP value < 0.01 
between PBS (diseased control group) and both AAV5 (CMV-Tregitope 167) 
treated and the healthy control group. 
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stained tissue sections. The score was calculated using the 
following criteria: percentage of  area involved, number 
of  follicle aggregates, edema, fibrosis, erosion/ulceration, 
crypt loss, and infiltration of  mononuclear and polymor-
phonuclear cells. The histological scoring showed that the 
AAV5 (CMV-Tregitope 167) pre-treated mice presented a 
decreased severity of  colitis as compared to the diseased 
control group (Figure 3D) as a result of  lower levels of  
inflammation, namely decreased cellular infiltrations, little 
crypt loss and the absence of  erosions and ulceration 
(Figure 4). 
The TNBS induced colitis model is characterized by 
the local infiltration of  CD4+ T cells in the intestinal 
mucosa[32]. Immunohistochemical staining of  the colonic 
tissues for CD4+ showed that, at the day of  sacrifice, in-
flammatory cell infiltrates were present in TNBS treated 
mice with or without administration with Tregitope 167 
and that these cellular infiltrates consisted mainly of  
CD4+ cells. For both TNBS treated groups CD4+ T 
cell infiltrates were observed in the sub-epithelial layer 
and the lamina propria. CD4+ T cell infiltrates were also 
present in the muscularis mucosa layer of  the diseased 
control mice, but were absent in the AAV5 (CMV-Tregi-
tope 167) pre-treated group (Figure 5). 
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Figure 3  Adeno associated virus serotype 5 mediated delivery of regulatory T-cell epitope 167 alleviates colonic inflammation as determined at the day of 
sacrifice. Mice were injected intravenously with either phosphate-buffered saline (PBS) or adeno associated virus (AAV) 5 [cytomegalovirus (CMV) promoter T-cell 
epitopes (Tregitope) 167]. Ten days after AAV-mediated Tregitope delivery acute colitis was initiated by intra-rectal administration of 1.5 mg trinitrobenzene sulfonate 
(TNBS) in 40% ethanol followed by a second treatment with TNBS (0.75 mg in 20% ethanol) 8 d later. Control groups consisted of mice not treated by TNBS (healthy 
control group) and mice treated by TNBS only (diseased control group). Disease progression was assessed by changes in daily body weight as well as macroscopic 
and microscopic scores on the day of sacrifice. A: Animal body weight change on day 20 upon sacrifice. The values of body weight are expressed as a percentage of 
body weight on the day of the first TNBS treatment; B: Macroscopic disease score. The disease activity index consist of a combination of body weight loss, loose stool 
and visible fecal blood scores divided by 3 at the day of sacrifice; C: Assessment of colonic weight upon sacrifice as an index of disease-related intestinal wall thicken-
ing; D: Histological grading of colonic colitis scores. The histology damage score was calculated using the following criteria: percentage of area involved, number of 
follicle aggregates, edema, fibrosis, erosion/ulceration, crypt loss, and infiltration of mononuclear and polymorphonuclear cells. Individual mice are depicted; from the 
AAV5 (CMV-Tregitope 167) pre-treated group an outliner was removed. Animals were withdrawn from the study when their weight loss was > 25% of their original 
body weight. Overall for the healthy controls, n = 9; AAV5 (CMV-Tregitope 167) treated, n = 6; diseased controls, n = 6, were included in the analysis. The data were 
analyzed using a 1 way analysis of variance, followed by Dunn’s post hoc test for multiple comparisons. Data are presented as mean ± SD of all the mice. aP < 0.05, 
bP < 0.01 vs PBS (diseased control group). 
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Increase of regulatory markers expression in the 
intestinal mucosa and thymus of mice administered with 
Tregitope 167
The reported ability of  Tregitopes to both activate and 
induce Treg cells led us to further assess the presence of  
Treg-cell associated markers in the colonic tissues. 
Colon tissues were prepared and the presence of  
transcription factor Foxp3 was assessed by immunohisto-
chemistry, so as to determine whether regulatory T cells 
were present in the peri-colonic infiltrates[33]. Numerous 
Foxp3 positive cells were detected in the lamina propria 
and sub-epithelium of  the colon sections from mice 
treated with Tregitope 167 (Figure 6). Foxp3 positive cells 
were absent or sporadic in the colon of  healthy and dis-
eased control mice (Figure 6).
Thymus, mesenteric lymph nodes, liver and spleen tis-
sue were collected at the time of  sacrifice and the corre-
sponding lymphocyte populations were further assessed 
by flow cytometry analysis for the expression of  the CD4 
T cell surface marker and the Treg cell associated mark-
ers Foxp3[34], CD25[35] and GARP[36,37] (Figure 7A-F). The 
Foxp3 and GARP markers were significantly increased 
in the CD4+ T lymphocyte population in the thymus of  
the mice pre-treated with AAV5 (CMV-Tregitope 167), as 
compared to lymphocyte populations in the thymus of  
diseased and the healthy control mice (P < 0.05 and P < 
0.001 respectively, Figure 7G). CD4+ thymic lymphocyte 
population (mean ± SD, 11% ± 2%, n = 6) co-expressed 
Foxp3 and GARP in the thymus of  AAV5 (CMV-
Tregitope 167) pre-treated mice as compared to the 
Figure 4  Hematoxylin and eosin-stained paraffin section from colon tissue. A, B: Healthy control mice; C, D: Diseased control mice; E, F: Adeno associated 
virus (AAV) 5 [cytomegalovirus (CMV) promoter T-cell epitopes (Tregitope) 167] pre-treated mice. Histological evidence that AAV5 (CMV-Tregitope 167) ameliorates 
trinitrobenzene sulfonate (TNBS)-induced pathology. Images depicted of an HE-stained paraffin section of a representative mouse colon from each group at the mo-
ment of sacrifice. The images of the diseased control (C, D) demonstrated acute inflammation: elongated villi, abundant transmural cellular infiltrate, erosions and 
crypt loss as compared to both the AAV5 (CMV-Tregitope 167) pre-treated and healthy control mice. 
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thymic lymphocyte population of  diseased (mean ± SD, 
7% ± 3%, n = 6) and the healthy control groups (mean 
± SD, 6% ± 2%, n = 9), respectively (Figure 7G). Both 
the relative and absolute number of  Foxp3 expressing 
T cells were expanded in the thymus after AAV5 (CMV-
Tregitope 167) pre-treatment (Figure 7H). No significant 
differences in the expression of  Foxp3 and GARP in the 
lymphocyte populations of  the mesenteric lymph nodes, 
liver and spleen were identified.
DISCUSSION
Curative treatment approaches for Crohn’s disease and ul-
cerative colitis represent a significant unmet medical need. 
Regulatory T (Treg) cells are key players in maintaining 
peripheral tolerance, preventing autoimmune diseases 
and limiting chronic inflammation[33,38]. Therefore, novel 
strategies that aim for therapeutic tolerance induction and 
leverage Treg cells are currently being explored[39]. In the 
present study, the potential for AAV-mediated delivery 
of  an immunomodulatory peptide (Tregitope 167) was 
investigated. 
In this study, we demonstrate that the systemic AAV-
based delivery of  Tregitope 167 has the potential to pre-
vent the development of  fulminant colitis in a TNBS-
induced model of  IBD. Tregitope 167 was used in our 
study as its binding affinity for the MHC molecule in 
Balb/c mice is superior to Tregitope 289 (De Groot, 
manuscript submitted for publication). The significant 
decrease of  colonic inflammation in the Tregitope 167 
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Figure 5  Immunohistochemistry pictures depicting CD4 staining colon tissue. A, B: Healthy control mice; C, D: Diseased control mice; E, F: Adeno associated 
virus (AAV) 5 [cytomegalovirus (CMV) promoter T-cell epitopes (Tregitope) 167] pre-treated mice. Specific immunohistochemical staining showed inflammatory cell in-
filtrates present in trinitrobenzene sulfonate (TNBS) treated mice with or without administration with Tregitope 167 consisted of CD4 positive cells, localized in the sub-
epithelial layer, in the lamina propria (C-F) and for the diseased control also in the muscular layer (C,D). Depicted are representative data from a single mouse. 
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pre-treated mice was reflected in an overall weight gain 
and substantiated by a decreased disease activity index, 
colon weight and histology damage score at the time of  
sacrifice. Additionally, there was less mucosal inflamma-
tion in the AAV (CMV-Tregitope 167) pre-treated mice. 
This therapeutic benefit corresponded with increases in 
the relative number of  T cells expressing regulatory T cell 
markers in the colon tissues and among thymic lympho-
cytes of  the Tregitope 167-treated mice.
IBD patients do not present defects in regulatory T 
cell function or phenotype[40-42] and by consequence are 
more likely to benefit from therapies aiming at inducing 
and expanding Treg cells than patients affected by other 
autoimmune diseases. Tregitope 167 has the potential to 
both activate nTreg cells and induce iTreg cells[15,16] and 
may be suitable as a novel therapeutic agent for IBD. 
However, the use of  immunomodulatory peptides in clin-
ical applications for IBD has been hindered by difficulties 
associated with the systemic delivery of  the therapeutic 
peptides in sufficient quantity and concentration to the 
target tissues[17-19]. AAV has proven to be both effective 
and safe as a gene therapy delivery vector in the clin-
ic[20-22]. Therefore, AAV-mediated delivery of  Tregitopes 
was explored in this study. The AAV serotype 5 (AAV5) 
was used since pre-existing immunity to AAV5 in humans 
has been shown to be low[28,43]. Our data demonstrate that 
AAV5-mediated delivery may be an efficient approach for 
stable administration of  Tregitopes in vivo. Further studies 
will need to be performed to determine the duration of  
the immunological tolerance that is evoked by induction 
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Figure 6  Immunohistochemistry pictures depicting forkhead Box-P3 staining colon tissue. A, B: Healthy control mice; C, D: Diseased control mice; E, F: Adeno 
associated virus (AAV) 5 [cytomegalovirus-regulatory (CMV) promoter T-cell epitopes (Tregitope) 167] pre-treated mice. Colon tissue were prepared and assessed by 
immunohistochemistry for the expression of the transcription factor forkhead Box-P3 (Foxp3) as a marker for regulatory T cells. Numerous Foxp3 positive cells were 
detected in the lamina propria and sub-epithelium of the colon sections from mice treated with Tregitope 167 (E, F). Foxp3 positive cells were rarely present in the 
colon of healthy and diseased control mice (A-D). Depicted are representative data from a single mouse.  
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Figure 7  Adeno associated virus serotype 5 mediated delivery of regulatory T-cell epitope 167 induces forkhead Box-P3 and glycoprotein A repetitions predomi-
nant expression in the CD4 positive thymic lymphocyte population. Thymus tissue was collected upon sacrifice. Cells suspensions were prepared and stained for the 
following markers: CD4, glycoprotein A repetitions predominant (GARP) and forkhead Box-P3 (Foxp3) before analysis by flow cytometry (FACSCalibur, BD Biosciences). A: 
Histogram Foxp3 cell count: healthy control; B: Histogram GARP cell count: healthy control; C: Histogram Foxp3 cell count: diseased control; D: Histogram GARP cell count: 
diseased control; E: Histogram Foxp3 cell count: adeno associated virus (AAV) 5 [cytomegalovirus (CMV) promoter T-cell epitopes 167] pre-treated group (grey, filled in) 
vs unstained control (black continuous line). Gating was done on the CD4 positive thymic lymphocyte population. Depicted are representative data from a single mouse; F: 
Histogram GARP cell count: AAV5 (CMV-Tregitope 167) pre-treated group (grey, filled in) vs unstained control (black continuous line). Gating was done on the CD4 posi-
tive thymic lymphocyte population. Depicted are representative data from a single mouse; G: Depicted are percentages of CD4 positive, Foxp3 positive and GARP positive 
thymic lymphocytes. Individual mice are depicted; for the a AAV5 (CMV-Tregitope 167) pre-treated group one mouse did not have a thymus and therefore n = 6 mice were 
included in this analysis. The data were analyzed using a 1 way analysis of variance, followed by Dunn’s post hoc test for multiple comparisons. Data are presented as mean 
± SD of all the mice. aP < 0.05, bP < 0.01 vs phosphate-buffered saline (PBS) (diseased control group) or healthy control; H: Both the relative and absolute number of Foxp3 
expressing T cells were expanded in the thymus after AAV5 (CMV-Tregitope 167) pre-treatment. Mean % of lymphocytes expressing Foxp3 in the thymus of the three groups 
are depicted; for the AAV5 (CMV-Tregitope 167) pre-treated group one mouse did not have a thymus and therefore n  = 6 mice were included in this analysis.  
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and activation of  Treg cells. 
Regulatory T (Treg) cells are considered to be essential 
in the counter-regulation of  inflammatory reactions and 
Foxp3 is considered as a marker of  the regulatory phe-
notype[34,44,45]. Staining for Foxp3 in mice pre-treated with 
Tregitope 167 revealed the presence of  Foxp3 positive 
cells in the lamina propria and sub-epithelium of  the co-
lon sections. Additionally, expression of  both Foxp3 and 
GARP were increased in the thymic CD4+ T lymphocyte 
population in mice pre-treated with AAV5 (CMV-Tregi-
tope 167), indicating an increase in activated regulatory 
T-cells[34,36,37,44,45]. The presence of  higher numbers of  acti-
vated regulatory T cells corresponded with the prevention 
of  fulminant intestinal inflammation in vivo in this TNBS 
model of  IBD. 
No increase in the Treg cell populations was observed 
in the mesenteric lymph nodes, liver and spleen in the 
current study. We hypothesize that this could be due to 
the duration of  the experiment and the timing of  the 
Treg cell evaluation. In other mouse models such as the 
model of  spontaneous encephalomyelitis, the de novo gen-
eration of  Treg cells was initiated intrathymically, and was 
followed by Foxp3 induction in peripheral tissue at later 
time points[46].
Tregitopes are T cell epitopes naturally located in im-
munoglobulins that bind to multiple MHC class Ⅱ alleles 
and induce Treg cell responses. We have demonstrated 
that antigen presenting cells (APCs) present Tregitopes 
to nTreg cells, engage feedback mechanisms promoting 
a tolerogenic APC phenotype, induce Treg cell expan-
sion, and modulate antigen-specific effector T cell re-
sponses (Cousens and De Groot, manuscript submitted 
for publication). Proportions of  APC expressing MHC 
Ⅱ, CD80, and CD86 are suppressed, consistent with re-
ported effects of  intravenous immunoglobulin[47] and of  
the immunoglobulin (Ig) G-derived peptide hCDR1[48]. 
The basic mechanism of  Tregitope tolerance induction 
is currently proposed to be as follows: (1) APC present 
Tregitopes to nTreg cells; (2) nTreg cells are activated to 
proliferate; (3) nTreg cells provide tolerogenic feedback 
signals to APC, modulating the APC phenotype; and 
(4) nTreg cells and tolerogenic APC together suppress 
antigen-specific T cell responses (Cousens and De Groot, 
manuscript submitted for publication).
A limitation of  the colitis model used in this study 
was the acute necrotizing enterocolitis, occurring in the 
first 3 d after the first TNBS treatment, a presentation 
of  disease which is unrelated to IBD[25]. Therefore the 
surviving number of  mice, included in the analysis was 
lower than anticipated, which, for some analysis, conflict-
ed with statistical analysis of  the data. As a consequence, 
a large variability in the colon mucosa cytokines levels 
was observed after TNBS induced experimental colitis 
and prevented an accurate analysis of  those parameters. 
Therefore, further development of  AAV mediated de-
livery of  Tregitope 167 in different experimental models 
of  inflammatory disease will be necessary to confirm the 
obtained results.
In summary, our data provide preliminary evidence 
supporting the potential use of  AAV-based Tregitope 
delivery as a therapy for the treatment of  IBD. Further 
investigations will permit to define the mechanism by 
which Tregitope exert their immune regulatory proper-
ties, the duration of  the effect, the ability of  Tregitopes 
to reduce disease that has already been established and 
their eventual impact on systemic immunity. 
Overall, this study identifies AAV-mediated delivery 
of  regulatory T-cell epitope 167 as a novel anti-inflam-
matory approach with the capacity to decrease intestinal 
inflammation and induce long-term remission in IBD.
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Background
The focal point in the search for novel treatment options in inflammatory bowel 
diseases (IBD) is tolerance induction. In other words, exploring different mecha-
nisms by which the immune system could maintain unresponsiveness to the an-
tigens in the mucosal environment which cause destructive immune responses 
and thereby disease activity in IBD patients. 
Research frontiers
The recently discovered regulatory T cell epitopes (Tregitopes) are highly 
promising peptides that were demonstrated to both activate and induce regula-
tory T cells in vitro and in vivo. Modulation of T cell responses with Tregitopes 
may contribute to the regulation of pathological inflammatory responses in IBD. 
However, the use of immunomodulatory peptides in clinical applications for IBD 
so far have shown that the in vivo delivery of these peptides for therapeutic 
purposes is hindered by difficulties in obtaining sufficient and stable peptide 
concentrations.
Innovations and breakthroughs
This study identifies adeno-associated virus (AAV)-mediated delivery of regula-
tory T-cell epitope as a novel anti-inflammatory approach with the capacity to 
decrease intestinal inflammation and induce long-term remission in IBD. 
Applications
The significance of the achievements to IBD relate to possible novel therapeutic 
approaches, which could aim at long term tolerance induction. The described 
study identifies a novel anti-inflammatory strategy with the capacity to ameliorate 
the intestinal inflammatory response and restore mucosal immune tolerance.
Terminology
Tregitopes are T cell epitopes naturally located in immunoglobulins that bind to 
multiple major histocompatibility complex class Ⅱ alleles and induce regulatory 
T cell responses. The non-pathogenic, replication-deficient AAV holds prom-
ise for gene therapy. The AAV vector has a good safety profile as it remains 
predominantly episomal. The therapeutic potential of AAV as a vector in gene 
therapy has also been demonstrated in a clinical setting in recent studies.
Peer review
This interesting paper is investigating the possibility of AAV mediated delivery 
of regulatory trinitrobenzene sulfonate (TNBS)  colitis. The major finding of the 
study was that systemic administration of AAV was associated with a marked 
decrease in the clinical and histological severity of the TNBS induced inflamma-
tory colitis parallel with an increase of the T lymphocytes expressing regulatory 
markers in the colon and thymus. Overall, this manuscript presents an interest-
ing approach opening new possibilities.
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